Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-10 5:34 pm Unchanged | 2025-01-10 | 13D | Sage Therapeutics, Inc. SAGE | BIOGEN INC. BIIB | 6,241,473 10.200% | 0 (Unchanged) | Filing History |
| 2024-11-12 1:24 pm Unchanged | 2024-09-30 | 13G | Biogen Inc. BIIB | VANGUARD GROUP INC | 16,677,806 11.440% | 0 (Unchanged) | Filing History |
| 2024-11-07 4:48 pm Sale | 2024-10-30 | 13G | Denali Therapeutics Inc. DNLI | BIOGEN INC. BIIB | 7,155,243 4.970% | -5,596,122 (-43.89%) | Filing History |
| 2024-11-04 11:20 am Purchase | 2024-09-30 | 13G | Biogen Inc. BIIB | VANGUARD GROUP INC | 16,677,806 11.440% | 2,156,464 (+14.85%) | Filing History |
| 2024-10-16 12:11 pm Purchase | 2024-09-30 | 13G | Biogen Inc. BIIB | STATE STREET CORP STT | 7,346,505 5.000% | 7,346,505 (New Position) | Filing History |
| 2024-08-16 6:40 pm Sale | 2024-08-14 | 13G | Sangamo Therapeutics, Inc. SGMO | BIOGEN INC. BIIB | 3,250,000 1.600% | -11,402,466 (-77.82%) | Filing History |
| 2024-08-07 4:10 pm Purchase | 2024-07-31 | 13G | Biogen Inc. BIIB | BlackRock Inc. BLK | 14,646,751 10.100% | 400,431 (+2.81%) | Filing History |
| 2024-02-12 7:11 pm Sale | 2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BIOGEN INC. BIIB | 14,652,466 8.260% | -9,767,691 (-40.00%) | Filing History |
| 2024-02-12 7:07 pm Sale | 2023-12-31 | 13G | Denali Therapeutics Inc. DNLI | BIOGEN INC. BIIB | 12,751,365 9.230% | -558,878 (-4.20%) | Filing History |
| 2024-02-12 4:01 pm Purchase | 2023-12-31 | 13G | Biogen Inc. BIIB | PRIMECAP MANAGEMENT CO | 16,264,481 11.220% | 563,905 (+3.59%) | Filing History |
| 2024-02-12 11:21 am Purchase | 2024-01-31 | 13G | Biogen Inc. BIIB | VANGUARD GROUP INC | 14,521,342 10.020% | 114,463 (+0.79%) | Filing History |
| 2024-02-12 10:50 am Purchase | 2023-12-29 | 13G | Biogen Inc. BIIB | VANGUARD GROUP INC | 14,406,879 9.940% | 2,430,256 (+20.29%) | Filing History |
| 2024-01-24 2:27 pm Sale | 2023-12-31 | 13G | Biogen Inc. BIIB | BlackRock Inc. BLK | 14,246,320 9.800% | -13,817 (-0.10%) | Filing History |
| 2023-09-28 4:38 pm Sale | 2023-09-26 | 13D | Reata Pharmaceuticals, Inc. RETA | BIOGEN INC. BIIB | 0 0.000% | -8,936,791 (Position Closed) | Filing History |
| 2023-08-07 5:21 pm Purchase | 2023-07-28 | 13D | Reata Pharmaceuticals, Inc. RETA | BIOGEN INC. BIIB | 8,936,791 23.400% | 8,936,791 (New Position) | Filing History |
| 2023-02-09 4:01 pm Sale | 2022-12-31 | 13G | Biogen Inc. BIIB | PRIMECAP MANAGEMENT CO | 15,700,576 10.900% | -56,829 (-0.36%) | Filing History |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | Biogen Inc. BIIB | VANGUARD GROUP INC | 11,976,623 8.320% | 439,324 (+3.81%) | Filing History |
| 2023-01-24 1:56 pm Purchase | 2022-12-31 | 13G | Biogen Inc. BIIB | BlackRock Inc. BLK | 14,260,137 9.900% | 523,183 (+3.81%) | Filing History |
| 2022-03-07 2:51 pm Unchanged | 2021-12-31 | 13G | Biogen Inc. BIIB | BlackRock Inc. BLK | 13,736,954 9.400% | 0 (Unchanged) | Filing History |
| 2022-02-10 12:21 pm Sale | 2021-12-31 | 13G | Biogen Inc. BIIB | PRIMECAP MANAGEMENT CO | 15,757,405 10.730% | -64,661 (-0.41%) | Filing History |